Seminar: Prof. Anna Moore

Theranostic nanophrobes for siRNA/miRNA therapy in cancer

9 September 2014 00:00 hrs.
Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route 289
Theranostic nanophrobes for siRNA/miRNA therapy in cancer

Prof. Anna Moore, Harvard Medical School, Dept. of Radiology, Charlestown, USA


Prof. Jolanda de Vries, Dept. of Tumor Immunology, RIMLS

09-09-2014 00:00:00Europe/AmsterdamTheranostic nanophrobes for siRNA/miRNA therapy in cancer Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route

Remarks / more information:

Moore , AnnaRNA interference is an innate cellular mechanism for post-transcriptional regulation of gene expression in which double-stranded ribonucleic acid inhibits the expression of genes with complementary nucleotide sequences. Its therapeutic potential is indisputable, considering that one can use this mechanism to silence virtually any gene with single-nucleotide specificity. Recently described phenomenon of miRNA silencing has been attributed to targeting about 60% of mammalian genes and is an important modulator in various pathologies.This presentation will focus on theranostic nanoprobes that utilizes siRNA/microRNA mechanisms for image-guided cancer therapy. Theranostic agents that we develop enable delivery of nucleic acid-based and combination therapies, optimization of targeted delivery, and assessment of efficacy through non-invasive imaging, which provides the necessary set of tools to accomplish this in authentic physiologic environments and across time.


  • Yoo B, Ghosh S, Kumar M, Moore A,Yigit M, Medarova Z. Design of nanodrugs for miRNA targeting in tumor cells. J Biomed Nanotechnol. 2014 Jun;10(6):1114-22.
  • Wang P, Schuetz C, Ross A, Dai G, Markmann J, Moore A. Immune rejection after pancreatic islet cell transplantation: in vivo dual contrast-enhanced MR imaging in a mouse  model.Radiology 2013; 266(3):822-830.
  • Ghosh SK, Uchida M, Yoo B, Ross AW, Gendler SJ, Gong J, Moore A, Medarova Z. Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model. Int J Cancer, 2013, 132:1860-1867.

<< back to all events